Meeting
2020 ASCO Virtual Scientific Program
Effect of anlotinib in advanced small cell lung cancer (SCLC) patients relapsed within three months after second-line treatment: A subgroup analysis from a randomized, double-blind phase II trial (ALTER 1202).
Authors
Jianhua Shi
Linyi Cancer Hospital, Linyi, China
Jianhua Shi , Ying Cheng , Qiming Wang , Kai Li , Lin Wu , Baohui Han , Gongyan Chen , Jianxing He , Jie Wang , Haifeng Qin , Xiao-Ling Li
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Small Cell Lung Cancer
Citation
J Clin Oncol 38: 2020 (suppl; abstr 9063)
DOI
10.1200/JCO.2020.38.15_suppl.9063
Abstract #
9063
Poster Bd #
256
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Docetaxel + ramucirumab (DR) versus docetaxel + placebo (D) as second-line treatment for advanced non-small cell lung cancer (NSCLC): A randomized, phase II, double-blind, multicenter trial in Japan.
First Author: Yukio Hosomi
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Updated results from the phase II study: Efficacy and safety of anlotinib plus sintilimab as second-line treatment for patients with advanced biliary tract cancers.
First Author: Shuiling Jin
Poster
2021 ASCO Annual Meeting
Penpulimab plus anlotinib as second-line treatment for the small cell lung cancer after failure of platinum-based systemic chemotherapy.
First Author: Changgong Zhang
Poster
2021 Gastrointestinal Cancers Symposium
Phase II study of anlotinib plus sintlimab as second-line treatment for patients with advanced biliary tract cancers.
First Author: Hong Zong